GERN - What's Going On With Cancer Focused-Geron Stock On Friday? | Benzinga
Friday, Geron Corporation’s (NASDAQ:GERN) shares are trading lower with a high session volume of 5.82 million compared to the average 100-day volume of 8.8 million, as per data from Benzinga Pro.
Thursday, the FDA’s Oncologic Drugs Advisory Committee voted in favor of the clinical benefit/risk profile of Geron’s imetelstat for blood cancer.
The company is seeking approval for transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.
By a 12-to-2 margin, the panel voted in favor of the benefits of imetelstat, stating that the associated risks and ...